Literature DB >> 3046811

Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.

D C Knoppert1, M Spino, R Beck, J J Thiessen, S M MacLeod.   

Abstract

Theophylline disposition (5.5 mg/kg administered intravenously) was studied in 12 patients with cystic fibrosis (CF) and 16 healthy control volunteers. Dietary controls and logs were used to minimize the influence of food on theophylline metabolism. Control subjects were restudied in random order on two subsequent occasions after 2 weeks of either pancreatic enzymes or placebo. Theophylline and its three main metabolites, 1-methyluric acid, 3-methylxanthine, and 1,3-dimethyluric acid, were analyzed in serum and urine by HPLC. The total body clearance, renal clearance, nonrenal clearance, and volume of distribution of theophylline were significantly greater (p less than 0.05) in patients with CF than in control subjects. The increased nonrenal clearance was the result of increased biotransformation to each of the three main metabolites. Patients with CF exhibited enhanced N-demethylation and 8-hydroxylation of theophylline, pathways that appear to be mediated by two different families of P-450 enzymes. Theophylline clearance after 2 weeks of pancreatic enzyme administration in the control subjects was the same as with placebo. Possible reasons for enhanced theophylline biotransformation in CF are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046811     DOI: 10.1038/clpt.1988.147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  Sedation with Propofol for Bronchoscopy in Cystic Fibrosis Lung Transplant Recipients.

Authors:  Carrie Ho; Don Hayes; Medhi Khosravi; Mark L Splaingard; Dmitry Tumin; Eric A Lloyd
Journal:  Lung       Date:  2018-05-24       Impact factor: 2.584

Review 3.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

4.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Enhanced drug metabolism in young children with cystic fibrosis.

Authors:  A C Parker; P Pritchard; T Preston; R L Smyth; I Choonara
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

Review 6.  Role of free radicals in the pathogenesis of cystic fibrosis.

Authors:  R K Brown; F J Kelly
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

7.  Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.

Authors:  A E Cribb; B Tsui; R Isbrucker; R T Michael; C T Gillespie; J Brown-Bonomo; P Barrett; T Levatte; K W Renton
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

8.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 9.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

10.  Linezolid pharmacokinetics in adult patients with cystic fibrosis.

Authors:  John A Bosso; Patrick A Flume; Susan L Gray
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.